SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-005759
Filing Date
2022-04-18
Accepted
2022-04-18 16:37:14
Documents
13
Period of Report
2022-04-13
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Document Format Files

Seq Description Document Type Size
1 8-K ktra-20220413.htm   iXBRL 8-K 62528
2 EX-3.1 ktra-ex3_1.htm EX-3.1 8028
  Complete submission text file 0000950170-22-005759.txt   200052

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ktra-20220413.xsd EX-101.SCH 2497
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ktra-20220413_pre.xml EX-101.PRE 11595
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ktra-20220413_lab.xml EX-101.LAB 18402
7 EXTRACTED XBRL INSTANCE DOCUMENT ktra-20220413_htm.xml XML 4873
Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 150 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 150 SAN DIEGO CA 92121 (858) 350-4364
Kintara Therapeutics, Inc. (Filer) CIK: 0001498382 (see all company filings)

IRS No.: 990360497 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-37823 | Film No.: 22832531
SIC: 2834 Pharmaceutical Preparations